Boehringer Ingelheim Pharmaceuticals Inc. Company Profile

News Articles [ 732 Associated News Articles listed on BioPortfolio]

BaroFold and Boehringer Ingelheim announce strategic alliance for protein refolding technology

BaroFold and Boehringer Ingelheim have entered into a non-exclusive technology and commercial license option agreement.Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s Pres...

Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates

Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called m...

Boehringer Ingelheim announces changes to Board of Managing Directors

The Shareholders of Boehringer Ingelheim have appointed Dr Joachim Hasenmaier to Boehringer Ingelheim’s Board of Managing Directors. The 52-year old will take over responsibility for the new Consume...

Boehringer Ingelheim acquires FX125L and somatotaxin portfolio rights

Boehringer Ingelheim and Funxional Therapeutics announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin...

Boehringer Ingelheim acquires Funxional Therapeutics inflammation portfolio

Boehringer Ingelheim and Funxional Therapeutics, have formed an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics’ FX125L compound and somatotaxin p...

Ensemble Therapeutics and Boehringer Ingelheim ink $186 milliion macrocycle drug pact

Ensemble Therapeutics announced the initiation of a research collaboration with Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against s...

Boehringer Ingelheim completes biosimilar adalimumab trial

Biopharmaceutical specialist Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) has completed its phase I trial for a biosimilar version of adalimumab.

Boehringer Ingelheim starts biosimilar rituximab trial

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) is starting a Phase III trial for a biosimilar version of rituximab.

Drugs and Medications [ 59 Associated Drugs and Medications listed on BioPortfolio]

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Dulcolax balance [Boehringer Ingelheim Pharmaceuticals Inc]

Boehringer-Ingelheim Consumer Health Care Products Dulcolax Balance® Drug Facts

Pradaxa [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for o...

PubMed Articles [ 106 Associated PubMed Articles listed on BioPortfolio]

Lessons from 54 years of pharmaceutical research.

Regulatory aspects of devices.

Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.

A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent...

Efficient Synthesis of a Small Molecule, Nonpeptide Inhibitor of LFA-1.

A three-stage process for the synthesis of LFA-1 inhibitor 1 from amine 4 with an overall yield of 65% is described. The key stage involves a Ph(3)PCl(2)-induced dehydration/cyclization of urea 6 foll...

Direct titanium-mediated conversion of ketones into enamides with ammonia and acetic anhydride.

A one-step conversion of ketones into N-acetyl enamides was developed. The process employs safe and inexpensive reagents, proceeds under mild conditions, and tolerates diverse functional groups. The a...

Clinical Trials [ 10 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a sin...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions

The objective of this study is to evaluate the comparative bioavailability between Tamsulosin Hydrochloride 0.4 mg Capsules (Teva Pharmaceuticals USA) and Flomax® 0.4 mg Capsules (Boehrin...

Vascular Access Clinical Trials Data Coordinating Center

Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine...

Companies [ 38 Associated Companies listed on BioPortfolio]

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group...

Boehringer Ingelheim Pharmaceuticals, Inc

Boehringer Ingelheim Corporation is the U.S. member of the Boehringer Ingelheim worldwide group of companies dedicated to the discovery, development, manufacture and marketing of innovative human and...

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the U.S. headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.